Latest filings (excl ownership)
15-12B
Securities registration termination
19 Nov 21
EFFECT
Notice of effectiveness
16 Nov 21
EFFECT
Notice of effectiveness
16 Nov 21
8-K
Sanofi completes acquisition of Kadmon
9 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 21
POS AM
Prospectus update (post-effective amendment)
9 Nov 21
25-NSE
Exchange delisting
9 Nov 21
POS AM
Prospectus update (post-effective amendment)
9 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 21
8-K
Submission of Matters to a Vote of Security Holders
5 Nov 21
10-Q
2021 Q3
Quarterly report
4 Nov 21
8-K
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results
4 Nov 21
DEFA14A
Additional proxy soliciting materials
27 Oct 21
8-K
Other Events
27 Oct 21
DEFA14A
Additional proxy soliciting materials
21 Oct 21
8-K
Other Events
21 Oct 21
DEFM14A
Proxy related to merger
4 Oct 21
PREM14A
Preliminary proxy related to merger
21 Sep 21
DEFA14A
Additional proxy soliciting materials
8 Sep 21
8-K
Sanofi to acquire Kadmon to further strengthen growth of transplant business
8 Sep 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
8-K
Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results
5 Aug 21
8-K
Other Events
19 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
12 May 21
10-Q
2021 Q1
Quarterly report
6 May 21
8-K
Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results
6 May 21
DEFA14A
Additional proxy soliciting materials
3 May 21
DEFA14A
Additional proxy soliciting materials
1 Apr 21
DEF 14A
Definitive proxy
1 Apr 21
8-K
Other Events
1 Apr 21
8-K
Kadmon Announces U.S. FDA has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease
10 Mar 21
S-8
Registration of securities for employees
5 Mar 21
10-K
2020 FY
Annual report
4 Mar 21
8-K
Kadmon Provides Business Update and Reports Fourth Quarter 2020 Financial Results
4 Mar 21
8-K
Entry into a Material Definitive Agreement
16 Feb 21
8-K
Kadmon Announces Proposed $150 Million Convertible Senior Notes Offering with Capped Call Transactions
10 Feb 21
8-K
Departure of Directors or Certain Officers
12 Jan 21
8-K
Kadmon Announces 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting
7 Dec 20
Latest ownership filings
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 22
4
Harlan Waksal
9 Nov 21
4
Cynthia Louise Flowers
9 Nov 21
4
John L Ryan
9 Nov 21
4
Arthur S Kirsch
9 Nov 21
4
Gregory S. Moss
9 Nov 21
4
Nancy Miller-Rich
9 Nov 21
4
Steven Meehan
9 Nov 21
4
David E Cohen
9 Nov 21
4
Tasos Konidaris
9 Nov 21
4
Kyle Carver
9 Nov 21
4
Eugene Bauer
9 Nov 21
SC 13D
Magnetar Financial LLC
17 Sep 21
SC 13G/A
Third Point LLC
28 May 21
4
Arthur S Kirsch
17 May 21
4
Harlan Waksal
17 May 21
4
Cynthia Schwalm
13 May 21
4
Nancy Miller-Rich
13 May 21
4
Arthur S Kirsch
13 May 21
4
David E Cohen
13 May 21
4
Eugene Bauer
13 May 21
4
Tasos Konidaris
13 May 21
4
Harlan Waksal
6 Apr 21
SC 13G/A
Consonance Capital Management LP
17 Feb 21
SC 13G/A
PERCEPTIVE ADVISORS LLC
16 Feb 21
SC 13G/A
Consonance Capital Management LP
16 Feb 21
SC 13G
Avidity Partners Management LP
16 Feb 21
SC 13G/A
Vivo Capital VIII, LLC
12 Feb 21
SC 13G/A
MeiraGTx Holdings plc
12 Feb 21
SC 13G
STATE STREET CORP
10 Feb 21
SC 13G
VANGUARD GROUP INC
10 Feb 21
SC 13G/A
BlackRock Inc.
29 Jan 21
SC 13G
Point72 Asset Management, L.P.
14 Jan 21
4
Gregory S. Moss
12 Jan 21
4
Harlan Waksal
12 Jan 21
4
Steven Meehan
12 Jan 21
4
John L Ryan
12 Jan 21
4
Kyle Carver
12 Jan 21
4
Harlan Waksal
10 Sep 20
4
Nancy Miller-Rich
13 Aug 20